237 related articles for article (PubMed ID: 23666966)
1. Tumor suppressor role of the CL2/DRO1/CCDC80 gene in thyroid carcinogenesis.
Ferraro A; Schepis F; Leone V; Federico A; Borbone E; Pallante P; Berlingieri MT; Chiappetta G; Monaco M; Palmieri D; Chiariotti L; Santoro M; Fusco A
J Clin Endocrinol Metab; 2013 Jul; 98(7):2834-43. PubMed ID: 23666966
[TBL] [Abstract][Full Text] [Related]
2. The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias.
Leone V; Ferraro A; Schepis F; Federico A; Sepe R; Arra C; Langella C; Palma G; De Lorenzo C; Troncone G; Masciullo V; Scambia G; Fusco A; Pallante P
Cancer Lett; 2015 Feb; 357(2):535-41. PubMed ID: 25497869
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.
Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
BMC Cancer; 2006 Nov; 6():260. PubMed ID: 17076909
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation signatures identify biologically distinct thyroid cancer subtypes.
Rodríguez-Rodero S; Fernández AF; Fernández-Morera JL; Castro-Santos P; Bayon GF; Ferrero C; Urdinguio RG; Gonzalez-Marquez R; Suarez C; Fernández-Vega I; Fresno Forcelledo MF; Martínez-Camblor P; Mancikova V; Castelblanco E; Perez M; Marrón PI; Mendiola M; Hardisson D; Santisteban P; Riesco-Eizaguirre G; Matías-Guiu X; Carnero A; Robledo M; Delgado-Álvarez E; Menéndez-Torre E; Fraga MF
J Clin Endocrinol Metab; 2013 Jul; 98(7):2811-21. PubMed ID: 23666970
[TBL] [Abstract][Full Text] [Related]
5. Expression of nicotinamide adenine dinucleotide phosphate oxidase flavoprotein DUOX genes and proteins in human papillary and follicular thyroid carcinomas.
Lacroix L; Nocera M; Mian C; Caillou B; Virion A; Dupuy C; Filetti S; Bidart JM; Schlumberger M
Thyroid; 2001 Nov; 11(11):1017-23. PubMed ID: 11762710
[TBL] [Abstract][Full Text] [Related]
6. Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer.
Pallante P; Federico A; Berlingieri MT; Bianco M; Ferraro A; Forzati F; Iaccarino A; Russo M; Pierantoni GM; Leone V; Sacchetti S; Troncone G; Santoro M; Fusco A
Cancer Res; 2008 Aug; 68(16):6770-8. PubMed ID: 18701502
[TBL] [Abstract][Full Text] [Related]
7. Dysadherin: expression and clinical significance in thyroid carcinoma.
Sato H; Ino Y; Miura A; Abe Y; Sakai H; Ito K; Hirohashi S
J Clin Endocrinol Metab; 2003 Sep; 88(9):4407-12. PubMed ID: 12970317
[TBL] [Abstract][Full Text] [Related]
8. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
9. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G
J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328
[TBL] [Abstract][Full Text] [Related]
10. PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration.
Chiappetta G; Valentino T; Vitiello M; Pasquinelli R; Monaco M; Palma G; Sepe R; Luciano A; Pallante P; Palmieri D; Aiello C; Rea D; Losito SN; Arra C; Fusco A; Fedele M
Oncotarget; 2015 Mar; 6(7):5310-23. PubMed ID: 25595894
[TBL] [Abstract][Full Text] [Related]
11. MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1alpha.
Leone V; D'Angelo D; Rubio I; de Freitas PM; Federico A; Colamaio M; Pallante P; Medeiros-Neto G; Fusco A
J Clin Endocrinol Metab; 2011 Sep; 96(9):E1388-98. PubMed ID: 21752897
[TBL] [Abstract][Full Text] [Related]
12. Thymosin beta-10 gene overexpression correlated with the highly malignant neoplastic phenotype of transformed thyroid cells in vivo and in vitro.
Califano D; Monaco C; Santelli G; Giuliano A; Veronese ML; Berlingieri MT; de Franciscis V; Berger N; Trapasso F; Santoro M; Viglietto G; Fusco A
Cancer Res; 1998 Feb; 58(4):823-8. PubMed ID: 9485041
[TBL] [Abstract][Full Text] [Related]
13. Let-7a down-regulation plays a role in thyroid neoplasias of follicular histotype affecting cell adhesion and migration through its ability to target the FXYD5 (Dysadherin) gene.
Colamaio M; Calì G; Sarnataro D; Borbone E; Pallante P; Decaussin-Petrucci M; Nitsch L; Croce CM; Battista S; Fusco A
J Clin Endocrinol Metab; 2012 Nov; 97(11):E2168-78. PubMed ID: 22965940
[TBL] [Abstract][Full Text] [Related]
14. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
15. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
[TBL] [Abstract][Full Text] [Related]
16. P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression.
Preto A; Reis-Filho JS; Ricardo S; Soares P
Pathol Res Pract; 2002; 198(7):449-54. PubMed ID: 12234063
[TBL] [Abstract][Full Text] [Related]
17. Expression, regulation and function of autotaxin in thyroid carcinomas.
Kehlen A; Englert N; Seifert A; Klonisch T; Dralle H; Langner J; Hoang-Vu C
Int J Cancer; 2004 May; 109(6):833-8. PubMed ID: 15027116
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein e expression in anaplastic thyroid carcinoma.
Ito Y; Takano T; Miyauchi A
Oncology; 2006; 71(5-6):388-93. PubMed ID: 17690558
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of miR-181b promotes apoptosis by targeting CYLD in thyroid papillary cancer.
Li D; Jian W; Wei C; Song H; Gu Y; Luo Y; Fang L
Int J Clin Exp Pathol; 2014; 7(11):7672-80. PubMed ID: 25550803
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.
Pavelić K; Dedivitis RA; Kapitanović S; Cacev T; Guirado CR; Danić D; Radosević S; Brkić K; Pegan B; Krizanac S; Kusić Z; Spaventi S; Bura M
Mutat Res; 2006 Jul; 599(1-2):45-57. PubMed ID: 16698048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
